Skip to content

GLP-1 dose conversion chart: what the FDA labels say

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

There is no GLP-1 dose conversion chart between different medicines in any FDA label. Tirzepatide, semaglutide, liraglutide, dulaglutide and orforglipron each have their own milligram scale. The only label conversions are between semaglutide products, such as Wegovy injection to Wegovy tablets. For any other switch, the new brand's label gives only its starting dose, and your prescriber decides your dose.

Source: FDA label (DailyMed)

Key takeaways

  • No FDA label converts a dose between different GLP-1 molecules, such as Mounjaro to Wegovy.
  • Label conversions exist only within semaglutide, such as Wegovy 2.4 mg injection to the Wegovy 25 mg tablet.
  • Rybelsus 7 mg pairs with Ozempic tablets 4 mg, 14 mg with 9 mg, only after the first 30 days of treatment.
  • Switching between different molecules? The new label gives only its starting dose. Your prescriber decides your dose.
  • The Zepbound, Wegovy, Saxenda and Foundayo labels don't recommend using them with another GLP-1 medicine.

Every strength of every GLP-1 medicine

Strengths, schedule and pack size from each FDA label
MedicineFormTakenLabel schedule (mg)Other strengthsDoses per fill
ZepboundKwikPen (multi-dose, 4 weekly doses)weekly2.5 → 5 → 7.5 → 10 → 12.5 → 15Not listed4
ZepboundMulti-dose vial (4 weekly doses)weekly2.5 → 5 → 7.5 → 10 → 12.5 → 15Not listed4
ZepboundSingle-dose penweekly2.5 → 5 → 7.5 → 10 → 12.5 → 15Not listed4
ZepboundSingle-dose vialweekly2.5 → 5 → 7.5 → 10 → 12.5 → 15Not listed4
MounjaroKwikPen (multi-dose, 4 weekly doses)weekly2.5 → 5 → 7.5 → 10 → 12.5 → 15Not listed4
MounjaroMulti-dose vial (4 weekly doses)weekly2.5 → 5 → 7.5 → 10 → 12.5 → 15Not listed4
MounjaroSingle-dose penweekly2.5 → 5 → 7.5 → 10 → 12.5 → 15Not listed4
MounjaroSingle-dose vialweekly2.5 → 5 → 7.5 → 10 → 12.5 → 15Not listed1
WegovySingle-dose pen (7.2 mg pen is branded WEGOVY HD)weekly0.25 → 0.5 → 1 → 1.7 → 2.4 → 7.2Not listed4
WegovyTablet (once daily)daily1.5 → 4 → 9 → 25Not listed30
OzempicMulti-dose single-patient-use pen (4 weekly doses per pen at the maintenance dose; the 2 mg/3 mL pen delivers 4 doses of 0.25 mg plus 2 doses of 0.5 mg, or 4 doses of 0.5 mg)weekly0.25 → 0.5 → 1 → 2Not listed4
OzempicTablet (once daily; shares a label with Rybelsus, not substitutable mg-to-mg)daily1.5 → 4 → 9Not listed30
FoundayoTablet (once daily)daily0.8 → 2.5 → 5.5 → 9 → 14.5 → 17.2Not listed30
RybelsusTablet (once daily)daily3 → 7 → 14Not listed30
SaxendaMulti-dose single-patient-use pen, 18 mg per 3 mL pen (6 daily doses of 3 mg per pen; sold in cartons of 3 or 5 pens)daily0.6 → 1.2 → 1.8 → 2.4 → 3Not listed30
TrulicitySingle-dose penweekly0.75 → 1.5 → 3 → 4.5Not listed4

If you searched for a GLP-1 dose conversion chart, you probably want one line: “my dose of this medicine equals that dose of the other one.” The FDA labels don’t draw that line between different medicines. They do publish a short list of conversions inside one molecule, semaglutide, and this page gives those in full. The chart above lines up the dose steps of every GLP-1 brand side by side so you can see each scale. The rows are not equal to one another.

The conversions the labels do publish

Every conversion in an FDA label we hold is between two semaglutide products. These are the labels’ own instructions.

Switching from Switching to What the label says
Wegovy 2.4 mg injection, weekly Wegovy 25 mg tablet, daily Start the 25 mg tablet one week after the last injection.
Wegovy 25 mg tablet, daily Wegovy 2.4 mg injection, weekly Start the 2.4 mg injection the day after the last tablet. If the 25 mg tablet is not tolerated, the label says to consider the 1.7 mg injection.
Ozempic 0.5 mg injection, weekly Rybelsus 7 mg or 14 mg, daily Start the tablet one week after the last injection.
Ozempic 0.5 mg injection, weekly Ozempic tablets 4 mg or 9 mg, daily Start the tablet one week after the last injection.
Rybelsus 7 mg, daily Ozempic tablets 4 mg, daily Only after the first 30 days of treatment. Start the new tablet the day after the last one.
Rybelsus 14 mg, daily Ozempic tablets 9 mg, daily Only after the first 30 days of treatment. Start the new tablet the day after the last one.

Here’s how one row reads. Say your prescriber moves you from Wegovy 2.4 mg injection to the Wegovy 25 mg tablet, and your last injection was on a Monday. The label says to start the tablet one week after that, so the following Monday.

The Rybelsus and Ozempic tablet pairs work in both directions: Ozempic tablets 4 mg to Rybelsus 7 mg, and 9 mg to 14 mg. The label says plainly that the two tablet brands “are not substitutable on a mg-to-mg basis,” which is why 7 mg of one becomes 4 mg of the other.

Notice what the table leaves out. The Ozempic injection instructions cover only the 0.5 mg dose. The labels say nothing about moving from 1 mg or 2 mg of Ozempic to a tablet. And the Wegovy label’s switching section covers only Wegovy’s own injection and tablets.

Every other switch: the label gives a starting dose

For any switch between different molecules, such as Mounjaro to Wegovy, Ozempic to Mounjaro or Wegovy to Zepbound, the new medicine’s label gives no conversion. It gives its own starting dose, the same one a person new to GLP-1 medicines would get:

  • Zepbound: 2.5 mg once weekly.
  • Mounjaro: 2.5 mg once weekly.
  • Wegovy injection: 0.25 mg once weekly. Wegovy tablets: 1.5 mg once daily.
  • Ozempic injection: 0.25 mg once weekly.
  • Rybelsus: 3 mg once daily.
  • Foundayo: 0.8 mg once daily.
  • Trulicity: 0.75 mg once weekly.
  • Saxenda: 0.6 mg once daily.

That’s what the labels say. It isn’t a rule that every switch must start at the bottom. Your prescriber makes that call for you, based on how you’ve handled your current medicine. If you’re given a different starting dose after a switch, that’s their clinical judgment, and it’s fair to ask them why.

Mounjaro to Wegovy, and the other common pairs

Mounjaro and Wegovy. Mounjaro is tirzepatide. Wegovy is semaglutide. No label pairs their doses. The Wegovy injection label’s escalation (the step-by-step dose increases) runs from 0.25 mg to the 2.4 mg maintenance dose over 16 weeks. Our Mounjaro vs Wegovy comparison sets out what else differs, including approved uses.

Ozempic and Mounjaro. Both treat type 2 diabetes, and both are weekly injections. The Mounjaro label starts at 2.5 mg. See switching from Ozempic to Mounjaro.

Wegovy and Zepbound. Both are approved for weight reduction. Neither label converts doses from the other. See Wegovy to Zepbound and Zepbound to Wegovy.

Saxenda and Wegovy. Saxenda is liraglutide, taken daily. Wegovy is semaglutide, taken weekly. See Saxenda to Wegovy.

Why milligrams do not convert across medicines

Each molecule has its own dose scale, set by its own clinical trials. A milligram of tirzepatide and a milligram of semaglutide are the same weight of two different substances that act differently in the body. So 2.5 mg of Zepbound, a starting dose that is not approved for maintenance, is not a smaller version of 2.4 mg of Wegovy, a maintenance dose. Even two semaglutide tablets don’t match milligram for milligram.

Charts that pair, say, a tirzepatide dose with a semaglutide dose float around online. None of the FDA labels we hold contains one. If someone shows you such a chart, ask where its numbers come from.

Do not overlap two GLP-1 medicines

Zepbound, Wegovy, Saxenda and Foundayo each say that using them with another GLP-1 receptor agonist is not recommended. A switch replaces one medicine with the other. The label switches in the table each name a start day after the last dose of the old product. For other switches, the labels give no gap, so ask your prescriber for the date of your first dose of the new medicine.

Plan a switch

The switching planner shows, for any pair of products, the label’s own text on that switch, or says plainly that the label has none. To see every strength and pack size in one table, use the GLP-1 dose chart. Every instruction on this page comes from the prescribing information on DailyMed, and the sources below quote it.

Frequently asked questions

Is there an official GLP-1 dose conversion chart?

Not between different medicines. No FDA label we hold converts a dose of one GLP-1 molecule into a dose of another. The labels publish conversions only between semaglutide products: Wegovy injection and Wegovy tablets, Ozempic 0.5 mg injection and the semaglutide tablets, and Rybelsus and Ozempic tablets. Charts that pair other brands don't come from the labels.

What Wegovy dose equals 5 mg of Mounjaro?

No label says. Mounjaro is tirzepatide and Wegovy is semaglutide, two different molecules, and neither label pairs a dose of one with a dose of the other. The Wegovy injection label starts at 0.25 mg once weekly and raises the dose every 4 weeks. Your prescriber decides where you start after a switch.

What Mounjaro dose equals 1 mg of Ozempic?

No label says. The Mounjaro label gives no instructions for switching from another GLP-1 medicine. It states one starting dosage, 2.5 mg once weekly, raised in 2.5 mg steps after at least 4 weeks if more glycemic control (blood sugar control) is needed. Your prescriber decides the dose and when to start it.

Can I take two GLP-1 medicines while I switch?

The labels advise against it. Zepbound, Wegovy, Saxenda and Foundayo each say that using them together with another GLP-1 receptor agonist is not recommended. A switch means stopping one medicine and starting the other. The label switches on this page each give a start day after the last dose of the old product.

Sources (11)

  1. 1.
    Rybelsus and Ozempic tablets prescribing information, Table 1 (DailyMed)
    “Table 1. Switching Between Escalation or Maintenance Dosage of RYBELSUS and OZEMPIC Tablets. RYBELSUS 7 mg orally once daily = OZEMPIC Tablets 4 mg orally once daily. RYBELSUS 14 mg orally once daily = OZEMPIC Tablets 9 mg orally once daily.”
  2. 2.
    FDA label (DailyMed): Wegovy prescribing information, section 2.5
    “One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily.”
  3. 3.
    FDA label (DailyMed): Wegovy prescribing information, section 2.5
    “The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly.”
  4. 4.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.4
    “One week after discontinuing 0.5 mg of subcutaneous OZEMPIC injection, start 4 mg or 9 mg of OZEMPIC tablets orally once daily.”
  5. 5.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.4
    “One week after discontinuing 0.5 mg of subcutaneous OZEMPIC injection, start 7 mg or 14 mg of RYBELSUS orally once daily.”
  6. 6.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.3
    “When switching between RYBELSUS and OZEMPIC tablets, initiate the other semaglutide tablet product the day after discontinuing the previous semaglutide tablet product.”
  7. 7.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
    “RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis.”
  8. 8.
    FDA label (DailyMed): Zepbound prescribing information, section 1
    “ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  9. 9.
    FDA label (DailyMed): Wegovy prescribing information, section 1
    “Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
  10. 10.
    FDA label (DailyMed): Foundayo prescribing information, section 1
    “Concomitant use with another GLP-1 receptor agonist is not recommended.”
  11. 11.
    FDA label (DailyMed): Saxenda prescribing information, section 1
    “SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”